Just a quick point of reference to get some perspective on the share price as compared to another biotech type company
Yseterday's quarterly for Solagran SLA showed 32000 (115k year to date) in revenues and operating cash flow loss of 535 k with 600k cash at bank
SBN shows 166k in revenues (511k year to date - and rising exponentially at solid %) and net operating cash flow loss of 887k and shows 468k of cash in bank
SLA market cap is $75 million SBN market cap around $11 million
SLA sp around 50 cents SBN sp around 3 cents
AND SLA has its probs with opes prime (ANZ currently holds 42% of company and stock may get dumped at some point) after reaching a sp of around $1.50 within the last year.
A reasonable man would suggest that looking at the numbers and the future of the two companies that SBN is way undervalued, or SLA is way overvalued
Am I missing something here with this comparison??
Food for thought - interesting to hear what others say about this
SBN Price at posting:
0.0¢ Sentiment: None Disclosure: Held
